Nataliya Mar
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Gastroenterology top 10%
- Gastroesophageal reflux and treatments
Papers in
- Co-authors
- James J. Vredenburgh (3 shared papers)Jeffrey S. Wasser (1 shared paper)Robert R. Karpman (1 shared paper)Georgia Panagopoulos (1 shared paper)R. W. Graham (2 shared papers)Joshua Cohen (2 shared papers)Arash Rezazadeh Kalebasty (13 shared papers)Farshid Dayyani (1 shared paper)
- Journals
- Journal of Clinical Oncology (22 papers)Annals of Oncology (6 papers)Clinical Genitourinary Cancer (2 papers)Cancers (2 papers)Journal of Thrombosis and Thrombolysis (2 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Nataliya Mar
54 papers receiving 583 citations
Hit Papers
Peers
Comparison fields: 5 of 63
- Oncology 272
- Gastroenterology 47
- Surgery 298
- Pulmonary and Respiratory Medicine 185
- Dermatology 23
Countries citing papers authored by Nataliya Mar
This map shows the geographic impact of Nataliya Mar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nataliya Mar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nataliya Mar more than expected).
Fields of papers citing papers by Nataliya Mar
This network shows the impact of papers produced by Nataliya Mar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nataliya Mar. The network helps show where Nataliya Mar may publish in the future.
Co-authors
The 25 scholars most cited alongside Nataliya Mar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 86 | |
| 2 | LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) Hit paper breakdown → | 2023 | 84 |
| 3 | 2013 | 54 | |
| 4 | 2006 | 33 | |
| 5 | 2020 | 32 | |
| 6 | 2022 | 30 | |
| 7 | 1995 | 27 | |
| 8 | 2022 | 20 | |
| 9 | 2021 | 17 | |
| 10 | 2019 | 17 | |
| 11 | 2014 | 15 | |
| 12 | 2020 | 15 | |
| 13 | 2023 | 14 | |
| 14 | 2022 | 10 | |
| 15 | 2024 | 9 | |
| 16 | 2023 | 9 | |
| 17 | 2020 | 8 | |
| 18 | 2023 | 8 | |
| 19 | 2023 | 7 | |
| 20 | 2023 | 6 |
About Nataliya Mar
Nataliya Mar is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 65 papers that have together received 588 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (28 papers), Cancer Immunotherapy and Biomarkers (21 papers), Urinary and Genital Oncology Studies (18 papers), Prostate Cancer Treatment and Research (8 papers), Renal cell carcinoma treatment (5 papers), Cancer Research and Treatments (4 papers), Cancer Genomics and Diagnostics (4 papers) and PARP inhibition in cancer therapy (4 papers). The work is most often cited by research in Oncology (272 citations), Gastroenterology (47 citations), Surgery (298 citations), Pulmonary and Respiratory Medicine (185 citations) and Dermatology (23 citations). Nataliya Mar has collaborated with scholars based in United States, Spain and France. Frequent co-authors include James J. Vredenburgh, Jeffrey S. Wasser, Robert R. Karpman, Georgia Panagopoulos, R. W. Graham, Joshua Cohen, Arash Rezazadeh Kalebasty, Farshid Dayyani, Samer K. Khaled and Jonathan E. Rosenberg. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Genitourinary Cancer, Cancers and Journal of Thrombosis and Thrombolysis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.